#Germany #Petah Tikva #Isotopia #DSD Pharma #Isoprotrace

Isotopia Launches Isoprotrace® in Germany

Isotopia, a pioneer in the field of innovative radiopharmaceuticals, has marked a significant milestone by officially introducing Isoprotrace® in Germany. This launch is made possible through a strategic partnership with DSD Pharma, a reputable pharmaceutical distributor operating in Germany. Together, they aim to enhance the accessibility of advanced diagnostic solutions for healthcare providers across the nation, ensuring that patients receive timely and effective imaging and treatment options for prostate cancer.

Isoprotrace® is a state-of-the-art radiopharmaceutical product designed specifically for imaging prostate cancer. It utilizes a multi-dose kit that facilitates the quick and efficient preparation of Gallium (68Ga) Gozetotid solution for intravenous (IV) injection. After being radiolabeled with Gallium (68Ga) chloride solution, Isoprotrace® is indicated for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men diagnosed with prostate cancer in various clinical scenarios, including:

1. Primary staging of high-risk prostate cancer patients before primary curative therapy.
2. Suspected recurrence of prostate cancer based on elevated serum prostate-specific antigen (PSA) levels after initial treatment.

In Germany, prostate cancer remains one of the most prevalent forms of cancer among men, with over 70,000 new cases diagnosed each year. Accurate imaging plays a crucial role in achieving precise diagnoses and effective treatment planning, making Isoprotrace® a vital tool for healthcare professionals.

Tzachi Levy, General Manager of Isotopia's aseptic facility, expressed enthusiasm about the collaboration, stating, "We are thrilled to partner with DSD Pharma to bring Isoprotrace® to the German market. Germany is a key market for Isoprotrace®, and we are confident that this partnership will ensure the successful launch and accessibility of this innovative product for healthcare providers across the country."

Furthermore, Dr. Susanne Dorudi, Managing Director at DSD Pharma, echoed this sentiment, highlighting the groundbreaking nature of Isoprotrace®. "We are proud to launch Isoprotrace® in conjunction with Isotopia in Germany. This partnership allows us to provide German physicians with a cutting-edge imaging solution. We are excited about the potential impact of this product and look forward to its success in the German market."

Previously approved in the Netherlands, Isoprotrace® is expected to become available in over 10 EU countries in the near future. With a robust and dependable supply chain alongside a proven compliance record, Isotopia is committed to expanding patient access to this innovative product while enhancing diagnostic accuracy and treatment outcomes for prostate cancer.

About Isotopia

Isotopia is a frontrunner in the development of radiopharmaceuticals for molecular imaging and therapy, focused on delivering high-quality, advanced solutions for patient care through precision medicine.

About DSD Pharma

DSD Pharma is an established pharmaceutical distribution company operating in Austria, Germany, and Switzerland, specializing in state-of-the-art health solutions. DSD Pharma collaborates with leading global companies to bring innovative products to market, relying on a robust network and expertise in the pharmaceutical industry.